Crawford to plead guilty to financial conflict of interest: AP

Share this article:
Lester Crawford, the former FDA chief, is expected to tell a federal magistrate Tuesday that he lied about financial holdings in companies his agency regulated, the Associated Press reported. According to the AP report, Crawford’s lawyer, Barbara Van Gelder, said her client will plead guilty in response to charges from the Justice Department that Crawford falsely reported selling shares in companies governed by FDA rules. The firms were snack food manufacturer Pepsico and food product manufacturer Sysco. Crawford's ownership of those shares was prohibited under federal regulations, since the companies are to be “significantly regulated” by the FDA. The Justice Department also accused Crawford of conflict of interest, charging that as chairman of an FDA panel studying the problem of obesity, he and his wife owned at least $140,000 in stock in Pepsico, the mammoth snacks and drinks company, and Sysco, a major food distribution company. Crawford also violated financial reporting requirements -- alleged by court documents according to the AP -- by failing to disclose income from the sale of stock options in agriculture biotechnology firm Embrex, of whose board Crawford had been a member. Crawford resigned from the FDA in September 2005 but gave no reason for his decision to leave. He had held the top position for just two months but had been acting head of the regulatory agency for more than a year.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...